CISS vs ACAD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACAD Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Options & Structure while CISS counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, CISS trades at N/M Forward P/E with 24.6% operating margin (+249.0% YoY revenue) versus ACAD at 15.8x Forward P/E and 10.2% operating margin (+22.8% YoY). In options structure, CISS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CISS Revenue | ACAD Revenue | CISS Op. Margin | ACAD Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $220M | N/A | -110.6% | ACAD |
| FY2019 | N/A | $340M | N/A | -72.7% | ACAD |
| FY2020 | N/A | $440M | N/A | -64.9% | ACAD |
| FY2021 | N/A | $480M | N/A | -35.2% | ACAD |
| FY2022 | N/A | $520M | N/A | -43.2% | ACAD |
| FY2023 | $30M | $730M | 36.3% | -10.1% | CISS |
| FY2024 | $40M | $960M | 23.8% | 24.1% | ACAD |
| FY2025 | $30M | $1.07B | 3.9% | 9.8% | ACAD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CISS | ACAD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $991,199 | $3.0B | Larger Scale | ACAD |
| Trailing P/E Ratio Valuation | N/M | 8.3x | Lower Multiple | ACAD |
| Forward P/E Ratio Valuation | N/M | 15.8x | Lower Multiple | ACAD |
| Revenue Growth (YoY) Growth | +249.0% | +22.8% | Higher Growth | CISS |
| Operating Margin (TTM) Profitability | 24.6% | 10.2% | Higher Margin | CISS |
| Net Profit Margin Profitability | 27.4% | 30.1% | Higher Margin | ACAD |
| Return on Equity (ROE) Capital Efficiency | 17.1% | 31.4% | Higher ROE | ACAD |
| 52-Week Range Position Momentum | 20% ($0โ$6) | 8% ($16โ$31) | Stronger Trend | CISS |
| Beta / 30D Volatility Risk Regime | 11.91ฮฒ ยท 1054% Vol | 0.15ฮฒ ยท 90% Vol | Lower Realized Risk | ACAD |
| Unified Institutional Score Composite Signal | 33.6 / 100 (SELL) | 44.8 / 100 (HOLD) | Higher Composite | ACAD |